Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluating Tafenoquine Combinations for P. Vivax
NCT07533136Not yet recruiting
- Sponsor
- Walter Reed Army Institute of Research
- Start
- May 2026
- Primary completion
- Oct 2028
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tafenoquine in Plasmodium vivax malaria (4 arms), sponsored by Walter Reed Army Institute of Research. Primary endpoint: Rate of recurrence of Plasmodium vivax at 6 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
tafenoquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT07533136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533136.